The PER.C6 platform allows ProFibrix to manufacture recombinant human fibrinogen at levels that support the development and commercial rollout of new products.
The company’s lead product Fibrocaps is based on fibrinogen derived from human blood plasma and is a dry powder topical hemostat that stops acute and severe bleeding during surgery or after trauma injury. Initially recombinant fibrinogen will be developed for systemic applications in hemostasis and later on for the development of tissue repair products.
Jaap Koopman, CEO of ProFibrix, said: “The PER.C6 license gives us access to a manufacturing platform that has already been successfully tested by ProFibrix for high expression of biologically active recombinant fibrinogen. Our chief technology officer Bram Bout was one of the inventors of PER.C6 while at Crucell. His intimate knowledge of the platform in combination with our substantial in-house expertise on the biology of fibrinogen provides us with a strong competitive position in the hemostasis market.”